Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021

Brittany K. Smith; Andrew B. Janowski; Arim C. Fremont; Lucas J. Adams; Ya-Nan Dai; Christopher W. Farnsworth; Ann M. Gronowski; Stephen M. Roper; David Wang; Daved H. Fremont

doi:10.1128/mSphere.00450-21

mSphere (Aug 2021)

Progression of SARS-CoV-2 Seroprevalence in St. Louis, Missouri, through January 2021

Brittany K. Smith,
Andrew B. Janowski,
Arim C. Fremont,
Lucas J. Adams,
Ya-Nan Dai,
Christopher W. Farnsworth,
Ann M. Gronowski,
Stephen M. Roper,
David Wang,
Daved H. Fremont

Affiliations

Brittany K. Smith: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
Andrew B. Janowski: ORCiD; Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
Arim C. Fremont: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
Lucas J. Adams: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
Ya-Nan Dai: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
Christopher W. Farnsworth: ORCiD; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
Ann M. Gronowski: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
Stephen M. Roper: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
David Wang: ORCiD; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
Daved H. Fremont: ORCiD; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA

DOI: https://doi.org/10.1128/mSphere.00450-21
Journal volume & issue: Vol. 6, no. 4

Abstract

Read online

This study determined the percentage of children and adult samples from the St. Louis metropolitan area in Missouri with SARS-CoV-2 antibodies during three collection periods spanning April 2020 to January 2021. By January 2021, 20.68% of the tested individuals had antibodies. These results show the evolution of the SARS-CoV-2 pandemic in St. Louis, Missouri, and provide a snapshot of the extent of infection just prior to the start of mass vaccination.

Published in mSphere

ISSN: 2379-5042 (Online)
Publisher: American Society for Microbiology
Country of publisher: United States
LCC subjects: Science: Microbiology
Website: https://journals.asm.org/journal/msphere

About the journal